Skip to main content
. 2023 Aug 1;12(15):5063. doi: 10.3390/jcm12155063

Table 4.

Results of primary and secondary endpoints of atezolizumab, cemiplimab, and pembrolizumab trials.

Atezolizumab * Cemiplimab Pembrolizumab
Overall survival (months)
  • -

    20.2 vs. 14.7

  • -

    HR = 0.76 (95% CI [0.54, 1.09]) [21]

  • -

    NR vs. 14.2

  • -

    HR = 0.57 (95% CI [0.42, 0.77]) [18]
  • -

    26.3 vs. 13.4

  • -

    HR = 0.62 (95% CI [0.48, 0.8]) [25]
Progression-free survival (months)
  • -

    8.2 vs. 5.0

  • -

    HR = 0.59 (95% CI [0.43, 0.81]) [21]

  • -

    8.2 vs. 5.7

  • -

    HR = 0.54 (95% CI [0.43, 0.68]) [18]
  • -

    7.7 vs. 5.5

  • -

    HR = 0.50 (95% CI [0.39, 0.65]) [25]
Objective response (months)
  • -

    40.2% vs. 28.6%

  • -

    Median duration 38.9 vs. 8.3 [21]
  • -

    39% vs. 20%

  • -

    OR = 2.53 (95% CI [1.74, 3.69])

  • -

    Median duration 16.7 vs. 6.0 [18]
  • -

    46.1% vs. 31.1%

  • -

    Median duration 29.1 vs. 6.3 [25]
Mean ∆ Global Health Status/HRQoL GHS = 62.8 vs. 59.9 [23] ∆ GHS/HRQoL15.9 vs. −8.3 [18] QLQ-C30 = 6.95 (95% CI [3.29, 10.58]) vs. −0.88 (95% CI [−4.78, 3.02]) [24]

* Results refer to patients with PD-L1 expression in ≥50% of tumor cells or in ≥10% of tumor-infiltrating immune cells (high expression). Abbreviations: CI = confidence interval; GHS = Global Health Status; HR = hazard ratio; HRQoL = health-related quality of life; NR = not reached; OR = odds ratio; QLQ-C30 = Cancer Quality of Life Questionnaire.